FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3123163019> ?p ?o ?g. }

• W3123163019 abstract "Serious adverse event reporting guidelines have largely been developed for pharmaceutical trials. There is evidence that serious adverse events, such as psychological distress, can also occur in non-pharmaceutical trials. Managing serious adverse event reporting and monitoring in palliative care non-pharmaceutical trials can be particularly challenging. This is because patients living with advanced malignant or non-malignant disease have a high risk of hospitalisation and/or death as a result of progression of their disease rather than due to the trial intervention or procedures. This paper presents a number of recommendations for managing serious adverse event reporting that are drawn from two palliative care non-pharmacological trials.The recommendations were iteratively developed across a number of exemplar trials. This included examining national and international safety reporting guidance, reviewing serious adverse event reporting procedures from other pharmacological and non-pharmacological trials, a review of the literature and collaboration between the ACTION study team and Data Safety Monitoring Committee. These two groups included expertise in oncology, palliative care, statistics and medical ethics and this collaboration led to the development of serious adverse event reporting procedures.The recommendations included; allowing adequate time at the study planning stage to develop serious adverse event reporting procedures, especially in multi-national studies or research naïve settings; reviewing the level of trial oversight required; defining what a serious adverse event is in your trial based on your study population; development and implementation of standard operating procedures and training; refining the reporting procedures during the trial if necessary and publishing serious adverse events in findings papers.There is a need for researchers to share their experiences of managing this challenging aspect of trial conduct. This will ensure that the processes for managing serious adverse event reporting are continually refined and improved so optimising patient safety.ACTION trial registration number: ISRCTN63110516 (date of registration 03/10/2014). Namaste trial registration number: ISRCTN14948133 (date of registration 04/10/2017)." @default.
• W3123163019 created "2021-02-01" @default.
• W3123163019 creator A5007718775 @default.
• W3123163019 creator A5047529806 @default.
• W3123163019 creator A5051800138 @default.
• W3123163019 creator A5067899559 @default.
• W3123163019 creator A5069517316 @default.
• W3123163019 creator A5077865216 @default.
• W3123163019 date "2021-01-20" @default.
• W3123163019 modified "2023-09-25" @default.
• W3123163019 title "What should we report? Lessons learnt from the development and implementation of serious adverse event reporting procedures in non-pharmacological trials in palliative care" @default.
• W3123163019 cites W1903277992 @default.
• W3123163019 cites W1986360186 @default.
• W3123163019 cites W2007859292 @default.
• W3123163019 cites W2027863745 @default.
• W3123163019 cites W2099158591 @default.
• W3123163019 cites W2107036532 @default.
• W3123163019 cites W2110663591 @default.
• W3123163019 cites W2118866555 @default.
• W3123163019 cites W2123204506 @default.
• W3123163019 cites W2159418632 @default.
• W3123163019 cites W2171811563 @default.
• W3123163019 cites W2313356230 @default.
• W3123163019 cites W2327142206 @default.
• W3123163019 cites W2340890757 @default.
• W3123163019 cites W2529207539 @default.
• W3123163019 cites W2571167683 @default.
• W3123163019 cites W2580004407 @default.
• W3123163019 cites W2613905750 @default.
• W3123163019 cites W2736998550 @default.
• W3123163019 cites W2762787390 @default.
• W3123163019 cites W2800409811 @default.
• W3123163019 cites W2884440658 @default.
• W3123163019 cites W2894197002 @default.
• W3123163019 cites W2901996716 @default.
• W3123163019 cites W2902219846 @default.
• W3123163019 cites W2946486402 @default.
• W3123163019 cites W2970352640 @default.
• W3123163019 cites W2979858165 @default.
• W3123163019 cites W2982486814 @default.
• W3123163019 cites W3001884602 @default.
• W3123163019 cites W3011743042 @default.
• W3123163019 cites W3013636190 @default.
• W3123163019 cites W3023463185 @default.
• W3123163019 cites W3026597619 @default.
• W3123163019 cites W3041604959 @default.
• W3123163019 cites W3044975541 @default.
• W3123163019 cites W3047724610 @default.
• W3123163019 cites W3102538550 @default.
• W3123163019 cites W4236805817 @default.
• W3123163019 cites W4253289976 @default.
• W3123163019 cites W4297446959 @default.
• W3123163019 doi "https://doi.org/10.1186/s12904-021-00714-5" @default.
• W3123163019 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7819235" @default.
• W3123163019 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33472621" @default.
• W3123163019 hasPublicationYear "2021" @default.
• W3123163019 type Work @default.
• W3123163019 sameAs 3123163019 @default.
• W3123163019 citedByCount "1" @default.
• W3123163019 countsByYear W31231630192022 @default.
• W3123163019 crossrefType "journal-article" @default.
• W3123163019 hasAuthorship W3123163019A5007718775 @default.
• W3123163019 hasAuthorship W3123163019A5047529806 @default.
• W3123163019 hasAuthorship W3123163019A5051800138 @default.
• W3123163019 hasAuthorship W3123163019A5067899559 @default.
• W3123163019 hasAuthorship W3123163019A5069517316 @default.
• W3123163019 hasAuthorship W3123163019A5077865216 @default.
• W3123163019 hasBestOaLocation W31231630191 @default.
• W3123163019 hasConcept C118552586 @default.
• W3123163019 hasConcept C126322002 @default.
• W3123163019 hasConcept C159110408 @default.
• W3123163019 hasConcept C177713679 @default.
• W3123163019 hasConcept C197934379 @default.
• W3123163019 hasConcept C2779526319 @default.
• W3123163019 hasConcept C2991975920 @default.
• W3123163019 hasConcept C2994186709 @default.
• W3123163019 hasConcept C535046627 @default.
• W3123163019 hasConcept C545542383 @default.
• W3123163019 hasConcept C71924100 @default.
• W3123163019 hasConcept C98274493 @default.
• W3123163019 hasConceptScore W3123163019C118552586 @default.
• W3123163019 hasConceptScore W3123163019C126322002 @default.
• W3123163019 hasConceptScore W3123163019C159110408 @default.
• W3123163019 hasConceptScore W3123163019C177713679 @default.
• W3123163019 hasConceptScore W3123163019C197934379 @default.
• W3123163019 hasConceptScore W3123163019C2779526319 @default.
• W3123163019 hasConceptScore W3123163019C2991975920 @default.
• W3123163019 hasConceptScore W3123163019C2994186709 @default.
• W3123163019 hasConceptScore W3123163019C535046627 @default.
• W3123163019 hasConceptScore W3123163019C545542383 @default.
• W3123163019 hasConceptScore W3123163019C71924100 @default.
• W3123163019 hasConceptScore W3123163019C98274493 @default.
• W3123163019 hasIssue "1" @default.
• W3123163019 hasLocation W31231630191 @default.
• W3123163019 hasLocation W31231630192 @default.
• W3123163019 hasLocation W31231630193 @default.
• W3123163019 hasLocation W31231630194 @default.
• W3123163019 hasLocation W31231630195 @default.
• W3123163019 hasLocation W31231630196 @default.
• W3123163019 hasLocation W31231630197 @default.

• next